The rapid advances in percutaneous coronary intervention (PCI) technology and refinement in adjunctive pharmacological therapy have expanded and will continue to expand percutaneous treatment possibilities. Patients with complex or high-risk coronary lesions, due to extensive and diffuse multivessel, left main, or last remaining coronary artery disease (CAD)-that previously were not deemed suitable for PCI-are increasingly being treated with PCI (1) . Furthermore, PCI is increasingly considered an alternative to coronary artery bypass grafting (CABG) in selected patients other than those who have been refused for cardiac surgery.
Because periprocedural hemodynamic compromise and complications can occur rapidly, a growing number of high-risk PCI procedures are being performed with mechanical cardiac assistance, particularly in patients with poor left ventricular (LV) function. Although, the exact role of mechanical cardiac assistance in periprocedural risk management of complex and high-risk PCI procedures remains a matter of debate, the recently introduced percutaneous left ventricular assist devices (LVADs) might be a superior alternative to intra-aortic balloon pump (IABP) (2, 3) . To date, no large series concerning prophylactic percutaneous LVAD therapy in elective high-risk PCI have been published. Therefore, the purpose of this study was to investigate safety and feasibility of the Impella 2.5 (Abiomed Europe GmbH, Aachen, Germany), a minimally invasive percutaneous LVAD able to provide flow support up to 2.5 l/min, in elective high-risk PCI.
Methods
Study design. The Europella registry comprised patients from 10 tertiary PCI centers across Europe. It was designed to evaluate the safety and feasibility of all patients undergoing elective high-risk PCI with prophylactic mechanical cardiac support with the Impella 2.5. Patients with STsegment elevation myocardial infarction (MI) within 48 h or cardiogenic shock, or patients undergoing emergent PCI were excluded. The registry was supported by Abiomed Europe GmbH. The investigators had access to the data, and control of the data analysis and monitoring plan. Impella 2.5. As described earlier, the Impella 2.5 (Abiomed, Inc.) is a novel catheter-mounted (9-F) microaxial rotary bloodpump (12-F), designed for short-term circulatory support. Through a femoral approach it is positioned across the aortic valve into the LV with fluoroscopy. Expelling aspirated blood from the LV into the ascending aorta, the Impella 2.5 at its maximal rotation speed of 51,000 rpm is able to provide flow up to 2.5 l/min. The Impella 2.5 is CE (Conformité Européenne) marked for use up to 5 days and has recently received a 510(k) clearance for partial circulatory support for periods of up to 6 h from the U.S. Food and Drug Administration. Data collection. Baseline characteristics including PCIand Impella-related procedural characteristics were obtained from pre-specified clinical report forms. In addition, vital status and adverse events were collected at 30-day follow-up. Study end points and definitions. The primary safety end point was the incidence of major adverse cardiac and cerebral events defined as death, major bleeding requiring transfusion or surgery, MI, urgent CABG, or stroke at 30 days. Secondary safety end points included device malfunction, infection, vascular complications, renal failure, and hemolysis requiring transfusion. The primary feasibility end point included successful deployment, operation, and explantation of the Impella 2.5. All events were based on clinical diagnoses assigned by the patient's physician and were centrally adjudicated by an independent clinician. Statistical analysis. Data are presented as mean Ϯ SD for continuous variables and as number of patients and frequencies for categorical variables. EuroSCOREs were estimated with the online version of the European System for Cardiac Operative Risk Evaluation. Patients with an additive score sum Ն6 are considered at high risk.
Results
Between July 2004 and December 2007, a total of 144 consecutive patients received prophylactic circulatory support with Impella 2.5 during high-risk PCI. The age of patients and the prevalence of comorbid conditions were high. Moreover, 54% of the patients had a left ventricular ejection fraction (LVEF) Յ30%. Baseline and hemodynamic characteristics are detailed in Table 1 . Procedural characteristics. All PCI cases were qualified by the attending operators as high-risk procedures. The mean EuroSCORE was 8.2 Ϯ 3.4. In 43% of the cases, patients were refused for CABG. The procedure concerned left main coronary artery (LMCA) PCI, last patent vessel PCI, and complex multivessel disease (MVD) in 52%, 17%, and 82% of the cases, respectively. The procedural characteristics are detailed in Table 2 . Primary and secondary safety end points. At 30 days, the primary safety end point was reached in 12.4% of the cases. Death occurred in a total of 8 patients (1 intraprocedural death). There were no device-related deaths. MI did not occur, whereas stroke occurred in 1 patient during hospital stay. Major bleeding requiring transfusion or surgery occurred in 9 patients. With regard to the secondary safety end point, there were no cases of device malfunction. In 1 patient, an abscess developed at the groin where the Impella 2.5 was inserted. Vascular complications (i.e., spurious aneurysm, fistula) and renal failure occurred in 6 and 3 patients, respectively. Hemolysis requiring transfusion occurred in 1 patient. Primary efficacy end point. Successful passage through the femoral artery and implantation of the Impella 2.5 into the LV was achieved in all 144 patients. Both implantation and explantation of the Impella were considered easy or suitable in Ͼ99% of the cases. The safety and efficacy end points are detailed in Table 3 . 
Discussion
This study reports on the Europella registry, which to date is the largest cohort of patients who underwent an elective Impella 2.5-supported high-risk PCI. The 144 patients enrolled reflect a representative population of patients presenting to PCI centers in contemporary practice for highrisk procedures (i.e., due to complex or high-risk coronary lesions and/or multiple comorbidities). The present study shows that periprocedural support with the Impella 2.5 for elective high-risk PCI is safe and feasible and extends to encouraging findings with this novel percutaneous LVAD from 3 smaller case series (Table 4) (2,4,5 ).
There are currently many new percutaneous LVADs being developed, and supporters foresee that the growing accessibility of these devices will significantly expand the percutaneous treatment possibilities, particularly in highrisk PCI. However, 2 important questions need to be answered. First, what is the exact indication for mechanical cardiac assist in the setting of elective PCI? Second, what is the optimal device to be used during elective high-risk PCI procedures?
First, the guidelines are conservative with regard to the indications of mechanical cardiac assist in elective PCI, because they only recommend it in patients with very poor LV dysfunction or those considered at high risk of periprocedural hemodynamic collapse (6). However, is there a Baseline Characteristics (n ‫؍‬ 144) Values are mean Ϯ SD or n (%). CABG ϭ coronary artery bypass grafting; LVEF ϭ left ventricular ejection fraction; MI ϭ myocardial infarction; PCI ϭ percutaneous coronary intervention.
Procedural Characteristics (n ‫؍‬ 144) Values are mean Ϯ SD or n (%).
Abbreviations as in Table 1 .
End Points at 30-Day Follow-Up Table 3 End *n ϭ 143; 1 case not applicable due to intraprocedural death. MACCE ϭ major adverse cardiac and cerebral events; SAE ϭ serious adverse event; other abbreviations as in Table 1 .
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uniform definition of high-risk PCI? The Europella registry shows that there were several reasons for qualifying the PCI procedure as high-risk, thus necessitating mechanical cardiac support according to the attending operators. Interventions in an unprotected LMCA or LMCA equivalent, in a last patent vessel and in patients with complex coronary MVD, and low LV function were put forward to be reasons for employing the Impella 2.5 during the PCI procedure. These criteria, in absence of well-defined criteria and randomized controlled trials providing evidence for specific indications, are also the consensus amongst experts in the field (1) . Of note, employment of this rationale by the attending operators is retrospectively supported by the subgroup analysis in this study with regard to the mortality stratified by type of CAD and extent of LV dysfunction. Also criteria concerning comorbidities of patients seemed to be important in the decision to use periprocedural mechanical support, as shown by the high comorbidity profile of the patients included in the Europella registry. However, comorbidity was not frequently addressed as the main reason to use mechanical support. Important evidence for defining the indications of elective periprocedural support will likely emerge from 2 ongoing multicenter randomized trials-the PROTECT 2 (Prospective, Multicenter Randomized Controlled Trial) (NCT00562016) and the BCIS 1 (Balloonpump assisted Coronary Intervention Study)-randomizing between IABP versus Impella 2.5 periprocedural support, and elective IABP use versus conventional treatment (bailout IABP use), respectively. The first trial includes patients who have either MVD and an LVEF Ͻ35% or an unprotected LMCA and an LVEF Ͻ30%, whereas the latter includes patients with an LMCA lesion or a jeopardy score Ͼ8 and an LVEF Ͻ30%. Interestingly, the inclusion criteria of both trials are based on the severity of LV dysfunction and the extent of myocardium at jeopardy. Second, although mechanical cardiac assist might be an appealing treatment strategy for high-risk PCI, iatrogenic morbidity and complications due to the introduction of any invasive therapy should not outweigh the benefits. Currently, the most-used LV support device in elective highrisk PCI is the IABP. Reported usage rates of the IABP range from 4.9% to 64%, depending on the specific case mix of the studies. Although prophylactic IABP therapy for elective high-risk PCI is still debated, there seems to be a trend for improved survival when used, particularly due to a lower periprocedural complication rate (7, 8) . However, the IABP requires residual cardiac function and stable cardiac rhythm for effective use. In contrast, in safety and feasibility studies, percutaneous LVADs were shown to be capable of providing more adequate cardiac support compared with IABP, particularly during hemodynamic depression due to balloon inflation, in case of periprocedural emergencies such as coronary dissection or cardiogenic shock (4, 9) .
The main reasons impeding widespread implementation of percutaneous LVADs for use in elective high-risk Experience With Periprocedural Impella 2.5 Support in Elective High-Risk PCI Table 4 CAD ϭ coronary artery disease; other abbreviations as in Table 1 .
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